The year starts with good news for overweight and obese Brazilians: The National Health Surveillance Agency (Anvisa) has approved the first weekly injectable drug for the treatment of chronic diseases in Brazil. In the statement published in the Official Gazette of the Union (2) on Monday, The so-called semaglutide pen (2.4 mg), sold under the name Wegovy.
Semaglutide is already known in Brazilian pharmacies as a drug for controlling type 2 diabetes. – also under the names Ozempic and Rybelsus –However, as in the United States last year, the drug is now also indicated for people with some degree of obesity (Body Mass Index/BMI greater than or equal to 30 kg/m²) or overweight and co-morbidities.
How does semaglutide work?
Approved in Brazil, the new drug works by “mimicry” of GLP-1, a hormone produced by the human gut that signals the presence of food in that part of the body. in an interview with WorldPaulo Miranda, president of the Brazilian Society of Endocrinology and Metabolism (SBEM), said: This mechanism regulates the rate of gastric emptying.
In addition to regulating the excretion of the organ in question, GLP-1 causes a feeling of satiety in the hypothalamus of the brain, says Miranda. In this way, Wegovy will have the function of regulating this satiety scale, which often does not work for people with some degree of overweight, obesity or even diabetes.
Price and side effects
Semaglutide was already used in Brazil as: tag off — when a doctor prescribes a medicine specified in the leaflet for another disease or symptom – Danish pharmaceutical company Novo Nordisk requested Anvisa to use the pen at the end of 2021. neither the medicine in Brazil nor your price. In the USA, the monthly treatment fee is US$1,349 (approximately R$7,300).
Tests on 1961 adults with a high body mass index at 104-week follow-up showed no serious adverse events, although some gastrointestinal events such as nausea and vomiting were reported. This indicates the need for medical follow-up.
Source: Tec Mundo
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.
